Ngenla Den europeiske union - norsk - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - hypofysen og hypothalamus hormoner og analoger - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Dimethyl fumarate Neuraxpharm Den europeiske union - norsk - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Vydura Den europeiske union - norsk - EMA (European Medicines Agency)

vydura

pfizer europe ma eeig  - rimegepant - migrene lidelser - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Scemblix Den europeiske union - norsk - EMA (European Medicines Agency)

scemblix

novartis europharm limited - asciminib hydrochloride - leukemi, myelogen, kronisk, bcr-abl positiv - antineoplastiske midler - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Viread 245 mg Norge - norsk - Statens legemiddelverk

viread 245 mg

2care4 - tenofovirdisoproksilfumarat - tablett, filmdrasjert - 245 mg

Zinbryta Den europeiske union - norsk - EMA (European Medicines Agency)

zinbryta

biogen idec ltd - daklizumab - multippel sklerose - immunsuppressive - zinbryta er indisert hos voksne pasienter for behandling av tilbakefallende former for multippel sklerose (rms).

Tremfya Den europeiske union - norsk - EMA (European Medicines Agency)

tremfya

janssen-cilag international nv - guselkumab - psoriasis - immunsuppressive - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Sandimmun Neoral 25 mg Norge - norsk - Statens legemiddelverk

sandimmun neoral 25 mg

farmagon - ciklosporin - kapsel, myk - 25 mg

Sandimmun Neoral 25 mg Norge - norsk - Statens legemiddelverk

sandimmun neoral 25 mg

farmagon - ciklosporin - kapsel, myk - 25 mg

Sandimmun Neoral 25 mg Norge - norsk - Statens legemiddelverk

sandimmun neoral 25 mg

farmagon - ciklosporin - kapsel, myk - 25 mg